PARADIGM: OlaPArib And RADiotherapy In newly-diagnosed GlioblastoMa

Study Title: PARADIGM: OlaPArib And RADiotherapy In newly-diagnosed GlioblastoMa

Study Description: Short-course radiotherapy plus olaparib for newly diagnosed glioblastoma in patients unsuitable for radical chemoradiation: a randomised phase II clinical trial preceded by a lead-in phase I dose escalation study.

Study Design: Phase I dose escalation trial followed by a phase II randomised, double blind trial of radiotherapy plus placebo versus radiotherapy plus olaparib.

Trial Status: Open to recruitment

Chief Investigator: Prof Anthony Chalmers, Beatson West of Scotland Cancer Centre, Glasgow

Sponsor: University of Glasgow / Greater Glasgow and Clyde Health Board

Date Opened: 3rd March 2015

Planned Closure Date: Feb 2019

Target Recruitment: 164 patients

Open to New Sites: Yes

Contact Details: Clinical Trials Unit, Glasgow (CTUG)
Lorna Sweeting (Project Manager)
Cancer Research UK Clinical Trials Unit Glasgow
Beatson West of Scotland Cancer Centre
1053 Great Western Road
Glasgow G12 0YN
Tel: 00 44 (0) 141 301 7194
Fax: 00 44 (0) 141 301 7946
E-mail: [email protected]

For queries concerning Pharmacovigilance, or the documents to refer to for the clinical management of trial patients or those that are acting as the Reference Safety Information please contact:

The Pharmacovigilance Team email: [email protected] or

Telephone: 0141 211 0352/0203/3567/3968 or 0141 232 2068

Version of NCI Common Terminology Criteria for Adverse Events (CTCAE) being used for the study (if applicable): 4.03

Click here to download the CTCAE